Clinical Trial: Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: The Long-Term Safety and Tolerability of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD): An Open-Label Extension Study for Subjects Completing Stud

Brief Summary: The objective of this study is to evaluate the long-term effects and tolerability of ABT-089 in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).

Detailed Summary:
Sponsor: AbbVie (prior sponsor, Abbott)

Current Primary Outcome:

  • CAARS:Inv [ Time Frame: Day -1, Day 14, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24 ]
  • CGI-ADHD-S [ Time Frame: Day -1, Day 14, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24 ]


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • CAARS:Self [ Time Frame: Day -1, Day 14, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24 ]
  • BRIEF-A [ Time Frame: Day -1, Month 3, 6, 9, 12, 15, 18, 21, 24 ]
  • AAQOL [ Time Frame: Day -1, Month 3, 6, 9, 12, 15, 18, 21, 24 ]
  • WPAI [ Time Frame: Day -1, Month 3, 6, 9, 12, 15, 18, 21, 24 ]
  • FTND [ Time Frame: Day -1, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24 ]


Original Secondary Outcome: Same as current

Information By: AbbVie

Dates:
Date Received: May 28, 2008
Date Started: May 2008
Date Completion:
Last Updated: January 11, 2013
Last Verified: January 2013